Literature DB >> 19880571

Vaccines as a trigger for myopathies.

H Orbach1, A Tanay.   

Abstract

Vaccines are considered to be among the greatest medical discoveries, credited with the virtual eradication of some diseases and the consequent improved survival and quality of life of the at-risk population. With that, vaccines are among the environmental factors implicated as triggers for the development of inflammatory myopathies. The sporadic reports on vaccine-induced inflammatory myopathies include cases of hepatitis B virus, bacillus Calmette-Guérin, tetanus, influenza, smallpox, polio, diphtheria, diphtheria-pertussis-tetanus, combination of diphtheria with scarlet fever and diphtheria-pertussis-tetanus with polio vaccines. However, a significant increase in the incidence of dermatomyositis or polymyositis after any massive vaccination campaign has not been reported in the literature. In study patients with inflammatory myopathies, no recent immunization was recorded in any of the patients. Moreover, after the 1976 mass flu vaccination, no increase in the incidence of inflammatory myopathies was observed. Although rare, macrophagic myofasciitis has been reported following vaccination and is attributed to the aluminium hydroxide used as an adjuvant in some vaccines. Prospective multicenter studies are needed to identify potential environmental factors, including vaccines, as potential triggers for inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880571     DOI: 10.1177/0961203309345734

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

Review 1.  The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review.

Authors:  Angela Ceribelli; Maria De Santis; Natasa Isailovic; M Eric Gershwin; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 2.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

3.  Antisynthetase Syndrome Post Shingrix and Pneumovax Vaccinations, Possible Correlation.

Authors:  Alsayed Osman; Ahmad Almusa; Robert Ryad; Bahar Sumbulyuksel
Journal:  Cureus       Date:  2022-05-17

4.  Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report.

Authors:  Jennifer Chen Li; Jonathan Siglin; Michael S Marshall; Anat Stemmer-Rachamimov; Seth M Bloom; Kimberly G Blumenthal
Journal:  Open Forum Infect Dis       Date:  2022-09-27       Impact factor: 4.423

5.  Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines.

Authors:  Clodoveo Ferri; Michele Colaci; Carlo Umberto Manzini; Marco Sebastiani; Dilia Giuggioli; Lucio Brugioni
Journal:  Case Rep Rheumatol       Date:  2012-08-15

6.  Genetics and vaccines in the era of personalized medicine.

Authors:  John Castiblanco; Juan-Manuel Anaya
Journal:  Curr Genomics       Date:  2015-02       Impact factor: 2.236

7.  Geospatial Correlation of Amyopathic Dermatomyositis With Fixed Sources of Airborne Pollution: A Retrospective Cohort Study.

Authors:  David R Pearson; Victoria P Werth
Journal:  Front Med (Lausanne)       Date:  2019-04-24

8.  COVID-19 vaccine-associated dermatomyositis.

Authors:  Marlyn Wu; Maria Karim; Robin Ashinoff
Journal:  JAAD Case Rep       Date:  2022-03-02

9.  Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination.

Authors:  Wesam Gouda; Anwar Albasri; Faisal Alsaqabi; Humoud Y Al Sabah; Marwan Alkandari; Hassan Abdelnaby
Journal:  J Korean Med Sci       Date:  2022-02-07       Impact factor: 2.153

Review 10.  New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review.

Authors:  Marie-Therese Holzer; Martin Krusche; Nikolas Ruffer; Heinrich Haberstock; Marlene Stephan; Tobias B Huber; Ina Kötter
Journal:  Rheumatol Int       Date:  2022-08-08       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.